arrow
M

Martín Espinosa-Bravo

Leiden University
H指数:25
被引数:2,102

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Generation of chimeric antigen receptor T cells targeting p95HER2 in solid tumors

靶向p95HER2的嵌合抗原受体T细胞的生成

2024-11-182
OA
Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response
2024-07-111
OAAI
HER2-positive early breast cancer (EBC): treatment, toxicities and outcomes in a retrospective cohort of elderly patients (pts)
2024-05-020
PRE
Early-Stage Breast Cancer Detection in Breast Milk
2023-09-1411
OAAI
Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of- opportunity SOLTI TOT-HER3 pre-operative study
2023-08-0116
PRE
Genetic determinants of response to patritumab deruxtecan (HER3-DXd) in hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer: a correlative analysis from SOLTI TOT-HER3 trial
2023-03-011
PRE
ctDNA IN BREAST MILK FOR EARLY DETECTION OF PREGNANCY ASSOCIATED BREAST CANCER
2023-03-010
PRE
Clearance of ctDNA in triple-negative and HER2-positive breast cancer patients during neoadjuvant treatment is correlated with pathologic complete response
2022-11-296
OAAI
Effects of hospital facilities on patient outcomes after cancer surgery: an international, prospective, observational study

医院设施对癌症手术后患者预后的影响: 一项国际性、前瞻性、观察性研究

2022-07-0142
OAAI
EPClin vs OncotypeDx in invasive lobular cancer (ILC)
2022-05-010
OA
Health-Related Quality of Life After Nipple-Sparing Mastectomy: Results From the INSPIRE Registry (vol 29, pg 1722, 2022)
2022-04-290
OA
Prognostic value of ctDNA detection in patients with early breast cancer undergoing neoadjuvant therapy: A systematic review and meta-analysis

ctDNA检测对早期乳腺癌新辅助治疗患者预后价值的系统评价和meta分析

2022-03-0150
PRE
Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification

用于鉴定同源重组缺陷肿瘤和患者分层的RAD51测试的临床前体内验证

2022-02-1645
OA
Activity of patritumab deruxtecan, a HER3-directed antibody drug conjugate, in early breast cancer according to ERBB3 expression: Interim analysis results of a window-of-opportunity study (SOLTI-1805 TOT-HER3)
2022-02-151
PRE
Safety of conservative surgery with accelerated partial breast re-irradiation for isolated ipsilateral breast cancer recurrence regardless of immunohistochemical subtype. A multicentric prospective study
2022-02-151
PRE
ASO Visual Abstract: Health-Related Quality of Life After Nipple-Sparing Mastectomy: Results from the INSPIRE Registry
2021-11-100
PRE